Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by pabalooon Aug 13, 2020 10:58pm
79 Views
Post# 31406671

RE:RE:RE:RE:RE:Is Bausch The Canadian Outlicensing Partner ?

RE:RE:RE:RE:RE:Is Bausch The Canadian Outlicensing Partner ?Spitswapper you ignorant piece of ship. Your a watt that doesn't burn with acid! Why are you here regurgitating the same information we just herd on the conference call pretending you are privy to something new. Just flick off back to your bankrupt penny stock you moron! Are you proud your a mole in my pants. Trulance deal will be settled when it's settled in the mean time this company is a cash cow making millions every quarter. Don't worry about absorica it did nothing last quarter and we still would have made .10 without the tax costs. Yes generics are coming so what the market opportunity is huge if Sun wants to promote LD if not no worries soon Cipher will retain the rights to it and probably sell the rights back to Sun for 20 million just watch you deviant. 
Bullboard Posts